{"title":"慢性肾脏疾病和透析中的抗癌药物剂量","authors":"Anushree C. Shirali , Ben Sprangers","doi":"10.1053/j.ackd.2021.12.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>Patients with malignancies<span> have a high prevalence of kidney disease and are often treated with </span></span>antineoplastic agents<span> that undergo kidney metabolism or excretion or clearance via renal replacement therapies<span><span><span><span><span>. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and </span>immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both </span>pharmacodynamic and </span>pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use </span>in patients<span> with chronic kidney disease and end-stage kidney disease.</span></span></span></p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"29 2","pages":"Pages 208-216.e1"},"PeriodicalIF":2.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cancer Drug Dosing in Chronic Kidney Disease and Dialysis\",\"authors\":\"Anushree C. Shirali , Ben Sprangers\",\"doi\":\"10.1053/j.ackd.2021.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Patients with malignancies<span> have a high prevalence of kidney disease and are often treated with </span></span>antineoplastic agents<span> that undergo kidney metabolism or excretion or clearance via renal replacement therapies<span><span><span><span><span>. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and </span>immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both </span>pharmacodynamic and </span>pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use </span>in patients<span> with chronic kidney disease and end-stage kidney disease.</span></span></span></p></div>\",\"PeriodicalId\":7221,\"journal\":{\"name\":\"Advances in chronic kidney disease\",\"volume\":\"29 2\",\"pages\":\"Pages 208-216.e1\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in chronic kidney disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1548559521001671\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in chronic kidney disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559521001671","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Cancer Drug Dosing in Chronic Kidney Disease and Dialysis
Patients with malignancies have a high prevalence of kidney disease and are often treated with antineoplastic agents that undergo kidney metabolism or excretion or clearance via renal replacement therapies. Thus, the dosing of these agents, including classic chemotherapeutic drugs, targeted therapies, and immunotherapy, must take into account patients’ kidney function. In this review, we will discuss the pitfalls of accurate measurement of kidney function and how kidney disease affects both pharmacodynamic and pharmacokinetic properties of drugs. Lastly, we will discuss specific agents and summarize current dosing strategies for use in patients with chronic kidney disease and end-stage kidney disease.
期刊介绍：
The purpose of Advances Chronic Kidney Disease is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
